menu

Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

close
10 chapters
Play All
2.50 credits
2.5 hours
Chapter 1
Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes
Restart
Resume
Read full article
Choose a format
Media formats available:
Chapter 2
video Lipoprotein Particle Biomarkers and ASCVD for Segment 11891
Lipoprotein Particle Biomarkers and ASCVD
Chapter 3
video Who Gains the Most from Intensive Dyslipidemia Therapy? for Segment 11891
Who Gains the Most from Intensive Dyslipidemia Therapy?
Chapter 4
video Options for Dyslipidemia Therapies in 2020 for Segment 11891
Options for Dyslipidemia Therapies in 2020
Chapter 5
video Biology of Omega-3 Fatty Acids in Cardiovascular Disease:  What Do We Know for Segment 11891
Biology of Omega-3 Fatty Acids in Cardiovascular Disease: What Do We Know
Chapter 6
video Use of Omega-3 Fatty Acids in Patients with Diabetes for Segment 11891
Use of Omega-3 Fatty Acids in Patients with Diabetes
Chapter 7
video Lipid Management Guidelines – 2020 Focus on Icosapent Ethyl (IPE) for Segment 11891
Lipid Management Guidelines – 2020 Focus on Icosapent Ethyl (IPE)
Chapter 8
video Clinical Rundown: Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes for Segment 11891
Clinical Rundown: Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes
Chapter 9
video Life and Medicine in the Era of COVID-19 for Segment 11891
Life and Medicine in the Era of COVID-19
Chapter 10
video Clinical Rundown: Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes for Segment 11891
Clinical Rundown: Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes
Details
Presenters
Related
Comments
  • Overview

    This chapterized activity features 5 leading international experts who address the complex interrelationship of type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). In this “hot topic” program, the discussants review the release of recent data from clinical trials of adjunctive medicines with statin therapy focused on CV event risk reduction in patients with diabetes. The faculty also examine global guidelines and recommendations that address risk factor assessment and management. The use of LDL-lowering and adjunct agents will be explored, along with the new role of omega-3 fatty acids in current management algorithms. Authoritative practical considerations on lipid management in diabetes are discussed, as well as cardiovascular management during the COVID-19 pandemic. A pdf of the slides from this activity is available in the Resources section.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Yehuda Handelsman
    Research Grant – Amgen, Applied Therapeutics, AZ, BMS, BI, Gan & Lee, Lexicon, Novo Nordisk, Sanofi.
    Advisory/Consultant – Amarin, Amgen, Applied Therapeutics, AZ, BI, Esperion, Gilead, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi
    Speaker’s Bureau – Amarin, Amgen, AZ, Janssen, Merck, Novo Nordisk    

    Faculty:
    Deepak Bhatt
    Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, LevelEx, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda.

    Om Ganda – Nothing to disclose

    Jorge Plutzky
    CONSULTANT
    Amarin
    Amgen
    Cirius
    Esperion
    Merck   
    Novo Nordisk                       
    Sanofi/Regeneron              
    Vivus

    RESEARCH GRANTS:
    Boehringer Ingelheim

    Paul Rosenblit

    Speaker / Teaching Faculty:

    Amarin, Amgen, Merck

    Clinical Research Site Trials:

    Dexcom, Ionis (Akcea), Lilly,
    Mylan, Novo Nordisk

    Advisory / Consultant:

    Amarin, Akcea

    The following reviewer, Ben Caref, PhD, discloses that he has no financial relationship or relationship to products or devices with a commercial interest related to the content of this activity. 

  • Learning Objectives

    If the activity was planned and implemented in accordance with the Joint Accreditation Criteria for Accreditation to address interprofessional gaps/needs, use this statement (if unsure, check Initiative Summary):
    At the conclusion of this educational initiative, participants should be better prepared to:

    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that reduce ASCVD events beyond statin therapy in patients with diabetes
    • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches for managing diabetic patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of advanced-level clinicians, including endocrinologists, diabetes educators, PharmDs, NPs and PAs, and other allied healthcare professionals.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2.5 credits AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence, Inc., you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This chapterized activity features 5 leading international experts who address the complex interrelationship of type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). In this “hot topic” program, the discussants review the release of recent data from clinical trials of adjunctive medicines with statin therapy focused on CV event risk reduction in patients with diabetes. The faculty also examine global guidelines and recommendations that address risk factor assessment and management. The use of LDL-lowering and adjunct agents will be explored, along with the new role of omega-3 fatty acids in current management algorithms. Authoritative practical considerations on lipid management in diabetes are discussed, as well as cardiovascular management during the COVID-19 pandemic. A pdf of the slides from this activity is available in the Resources section.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Yehuda Handelsman
    Research Grant – Amgen, Applied Therapeutics, AZ, BMS, BI, Gan & Lee, Lexicon, Novo Nordisk, Sanofi.
    Advisory/Consultant – Amarin, Amgen, Applied Therapeutics, AZ, BI, Esperion, Gilead, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi
    Speaker’s Bureau – Amarin, Amgen, AZ, Janssen, Merck, Novo Nordisk    

    Faculty:
    Deepak Bhatt
    Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, LevelEx, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda.

    Om Ganda – Nothing to disclose

    Jorge Plutzky
    CONSULTANT
    Amarin
    Amgen
    Cirius
    Esperion
    Merck   
    Novo Nordisk                       
    Sanofi/Regeneron              
    Vivus

    RESEARCH GRANTS:
    Boehringer Ingelheim

    Paul Rosenblit

    Speaker / Teaching Faculty:

    Amarin, Amgen, Merck

    Clinical Research Site Trials:

    Dexcom, Ionis (Akcea), Lilly,
    Mylan, Novo Nordisk

    Advisory / Consultant:

    Amarin, Akcea

    The following reviewer, Ben Caref, PhD, discloses that he has no financial relationship or relationship to products or devices with a commercial interest related to the content of this activity. 

  • Learning Objectives

    If the activity was planned and implemented in accordance with the Joint Accreditation Criteria for Accreditation to address interprofessional gaps/needs, use this statement (if unsure, check Initiative Summary):
    At the conclusion of this educational initiative, participants should be better prepared to:

    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that reduce ASCVD events beyond statin therapy in patients with diabetes
    • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches for managing diabetic patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of advanced-level clinicians, including endocrinologists, diabetes educators, PharmDs, NPs and PAs, and other allied healthcare professionals.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2.5 credits AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence, Inc., you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20